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transplant recipients.
Background. Elderly transplant candidates represent an in-
creasingly important group on the waiting list for kidney trans-
plantation. Yet the factors that determine posttransplantation
outcomes in this population remain poorly defined.
Methods. We performed a population-based retrospective co-
hort study involving all patients aged 60 years or older who
received a first cadaveric kidney transplantation between 1985
and 2000 in the province of Quebec. The main outcomes were
patient survival, overall graft survival, and treatment failure
(patient death or graft loss within the first posttransplant year).
Survival analyses were performed using a Cox proportional
hazard model. Logistic regression identified factors predicting
treatment failure.
Results. On multivariate analysis, the modifiable factors asso-
ciated with patient survival were active smoking at transplan-
tation [hazard ratio (HR) 2.09, 95% confidence interval (CI)
1.22-3.60)], body mass index (BMI) (HR 1.34 for a 5-point in-
crease, 95% CI 1.05-1.67), and time on dialysis before trans-
plantation (HR 1.10 for a 1-year increase, 95% CI 1.02-1.18).
The only modifiable factor associated with graft survival was
active smoking at transplantation (HR 2.04, 95% CI 1.24-3.30).
Treatment failure was associated with time on dialysis before
transplantation (odds ratio for dialysis ≥2 years 3.28, 95% CI
1.34-7.9).
Conclusion. Our results show that active smoking, obesity,
and time on dialysis before transplantation are modifiable risk
factors associated with an increased risk of mortality after trans-
plantation in elderly recipients. They represent potential targets
for interventions aimed at improving patient and graft survival
in elderly patients.
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Kidney transplantation is considered to be the best
treatment option for end-stage renal disease (ESRD).
It offers a survival advantage [1] and improved qual-
ity of life [2] when compared to dialysis. These benefits
have been demonstrated for all patients suffering from
ESRD, regardless of their age [3]. In North America,
the mean age of patients on renal replacement therapy
has increased over the last decade [4, 5]. Patients aged
60 years and older have become an important propor-
tion of wait-listed individuals and of kidney transplant
recipients. For instance, in the last decade, the propor-
tion of subjects aged 65 years or more on the transplant
waiting list has risen from 6% to 13% [5]. Furthermore,
the proportion of kidney grafts allocated to patients aged
65 years or older has increased from 4% in 1993 to 11%
in 2003 [5].
Despite the fact that elderly patients with ESRD ben-
efit from kidney transplantation, worse patient and graft
survival have been reported in this age group when com-
pared to younger recipients [6–8]. To improve outcomes
in this patient population, identifying predictors of pa-
tient and graft survival is crucial. It will improve the se-
lection of elderly patients more likely to benefit from the
transplant procedure and flag therapeutic issues that can
be targeted while patients are on the waiting list. The
number of patients on the waiting list for kidney trans-
plantation has more than doubled over the last decade
in North America [4, 5]. Kidney grafts have become a
rare resource that should be optimized. From the per-
spective of organ allocation, improving the outcome of
older kidney recipients, who are at higher risk of graft
loss, can help optimize the use of organs. Furthermore,
the identification of factors associated with death or graft
loss in the early posttransplant period in this age group
is also important. In terms of organ allocation, such early
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events represent a waste of resources and a treatment
failure.
The factors that affect the clinical outcome of older
recipients are poorly defined. Although a previous re-
port [9] has addressed this issue, various questions remain
unanswered with regard to the role of factors, such as
time on dialysis before transplantation, body mass index
(BMI), and type of immunosuppression administered.
These factors have been associated with transplant out-
comes in general cohorts of kidney transplant recipients
[10, 11]. Yet their importance has never been addressed
in elderly recipients. They represent potential targets for
interventions aimed at improving patient and graft sur-
vival in elderly patients. Furthermore, factors associated
with early posttransplant death or graft loss are unknown
in this population.
We performed a population-based retrospective cohort
study to ascertain the factors which, at the time of trans-
plantation, can predict patient survival in recipients of
a first cadaveric kidney graft who were aged 60 years or
older in the province of Quebec. We identified the factors
that can predict graft survival and treatment failure (pa-
tient death or graft loss in the first posttransplant year)
in this patient population.
METHODS
Patients
This is a multicenter, population-based, retrospective
cohort study. All patients 60 years or older who received
a first cadaveric kidney transplant between January 1985
and June 2000 were identified from all centers offering
kidney transplantation in the province of Quebec. Of
these, we excluded patients who had received another
organ besides the kidney. We also excluded patients who
moved away from Quebec during follow-up and whose
outcome could not be determined. Patients were followed
up until death or November 2003, whichever came first.
Measurement
Chart review was performed to collect data. A data
abstraction sheet with operational definitions for each
variable served to minimize data collection errors. The
primary end point was patient survival. The two sec-
ondary end points were treatment failure and overall
graft survival. All patients were included for each of these
analyses. Patient survival was defined as the time elapsed
from kidney transplantation to death. Follow-up was not
censored for graft loss in this analysis. Overall graft sur-
vival was the time from transplantation until death, re-
turn to dialysis, or retransplantation. Treatment failure
was defined as patient death or graft loss within the first
posttransplant year. For these analyses, patient follow-up
was censored at the time of graft loss. We performed a sep-
arate analysis for treatment failure because such a poor
early outcome represents the waste of a rare resource and
is a concern in terms of allocation. We hoped to iden-
tify factors that would be strongly associated with this
poor outcome and could change allocation procedures
in elderly recipients. The modifiable outcome predictors
studied were BMI, smoking, type of immunosuppression,
time on dialysis before transplantation, donor age, and
human leukocyte antigen (HLA) mismatches. BMI was
measured at the time of transplantation. Smoking sta-
tus was assessed at the same time and was categorized
into never, past, and active smoker. A past smoker was
one who had reported smoking before transplantation,
but was not smoking at the time of transplantation. Pre-
transplant blood pressure, cholesterol, and triglyceride
levels were obtained as close as possible to the date of
transplantation, and in the year prior to this procedure
in all cases. Pretransplant levels of low-density lipopro-
tein (LDL) or high-density lipoprotein (HDL) choles-
terol were not routinely available in the charts and could
not be retrieved. Induction therapy was defined as the
use of polyclonal or monoclonal antibodies. The immuno-
suppressive agents at baseline were classified as follows.
Calcineurin inhibitors were dichotomized as tacrolimus
versus cyclosporine. The antiproliferative agents were
dichotomized as mycophenolate mofetil (MMF) versus
azathioprine or no antiproliferative agent. The number of
mismatches in A, B, and DR loci was established. Non-
modifiable risk factors were also measured to prevent
confounding. They included recipient age and gender,
cause of renal failure, vascular disease, high level of panel
reactive antibodies (PRA), and transplantation era. The
cause of renal disease was classified as glomerular, di-
abetic, hypertensive, or other. A patient was identified
as having a vascular disease if he/she had a history of
stroke, myocardial infarction, stable or unstable angina,
coronarography showing more than 70% stenosis on any
artery, or previous surgical revascularization or angio-
plasty in any arterial bed. A high PRA level was defined
as maximal PRA over 20%. The period of transplantation
was divided as transplantation before 1995 and transplan-
tation thereafter. Other predictive variables, such as cold
ischemia time, delayed graft function and rejection, were
not considered in the analyses as we aimed at establishing
factors which could help clinical decision-making at the
time of transplantation. The project was approved by the
ethics comity of the Centre Hospitalier de l’Universite´ de
Montre´al.
Statistical analysis
For continuous variables, descriptive statistics are re-
ported as means and standard deviations or medians and
quartiles, depending on whether or not the distribution
of the variable was symmetrical or skewed. Categorical
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variables are summarized in proportions. Crude rates of
patient survival and overall and death-censored graft sur-
vival were assessed at 1, 5, and 10 years posttransplant.
Kaplan-Meier curves were plotted to graphically track
survival.
In the regression models described below, missing data
for the independent variables were assumed to have
occurred at random. The pattern of missingness was
assumed to be arbitrary. Consequently, a multiple impu-
tation strategy with a Markov chain model was used to
generate the sequence of the imputed variables [12].
Our aim was to identify factors that could predict post-
transplant outcome before and at the time of transplanta-
tion, so as to pinpoint issues that could be addressed in the
management of wait-listed patients or in the selection of
potential recipients. In this light, because posttransplant
events, such as rejection, are unknown parameters in the
decision-making processes of clinicians at or before trans-
plantation, we have not included them in the regression
models. Regression analysis based on a Cox proportional
hazard model identified the factors, at the time of trans-
plantation, which could predict patient and graft survival.
Variables that were important clinically and those that
showed an association with outcome at an alpha level
<0.25 on univariate analysis were entered in the mul-
tivariate model. The assumption of proportionality for
each predicting variable was assessed visually by plotting
the log of the survival function or the negative log of the
log survival function on the y axis versus survival time
or log survival time on the x axis. When the assumption
of proportionality was not met, the hazard function was
plotted for each stratum of the independent variable. If
the hazard functions clearly crossed at some time point
in follow-up, an interaction term was created. This term
included the independent variable and the time at which
the hazard functions crossed. The multivariate model was
then supplemented with this interaction.
The factors that were associated with treatment failure
were assessed by logistic regression models. Independent
variables that were significant at an alpha level < 0.25 or
deemed important based on clinical judgment were en-
tered in the multivariate model. To prevent model overfit,
at most one variable per 10 observed events was included.
Therefore, variable selection was undertaken in the final
model. All statistical analyses were performed using SAS
version 8.2 software (SAS Institute, Cary, NC, USA).
RESULTS
Patient characteristics
From January 1985 to June 2000, 287 patients aged
60 years or older received a kidney graft in the province
of Quebec and were not recipients of other organ types.
Among these, 256 met the inclusion criteria and were
analyzed (Fig. 1). Patient and procedural characteristics
Received a kidney transplantation at age ≥60 years in Quebec from
January 1985 to June 2000 (no other organ type received)
N = 287
Received an organ from a deceased donor
N = 277
Received a first kidney transplantation
N = 260
Outcome could be determined
N = 256
Fig. 1. Patient flow chart.
are reported in Table 1. Most patients (75%) were aged
between 61 and 65 years at transplantation. Fourteen
percent of patients were diabetic, and 24% had docu-
mented vascular disease before transplantation. Median
donor age was 42 years and only 25% of donors were
aged 51 years or older. Patients received a calcineurin
inhibitor in 98% of cases, mostly cyclosporine (84%).
When tacrolimus was administered, it was in combina-
tion with MMF in 90% of patients. Only one patient re-
ceived sirolimus. All patients received prednisone. Dur-
ing the interval of data collection, two formulations of
cyclosporine were used (sandimmune and neoral). It was
not possible to identify cyclosporine formulation type by
chart review. Missing data on the independent variables
were not frequent. The highest percentage of missing data
was 11% for the data on HLA mismatches.
Patient and graft survival
Patient survival, overall and functional graft survival
are illustrated in Figure 2. Patient survival was 93% at
1 year, 74% at 5 years, and 33% at 10 years. Overall graft
survival was 88% at 1 year, 67% at 5 years, and 28%
at 10 years. However, when patient death was not con-
sidered as graft loss (functional graft survival), graft sur-
vival reached 95% at 1 year, 87% at 5 years, and 81% at
10 years. Death (Table 2) was due to cardiovascular dis-
ease in 46%, to neoplasia in 29%, and to infection in 23%
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Table 1. Patient characteristics at baseline (N = 256)
Median recipient age years (IQR) 63 (61–65)
Recipient gender-males (%) 175 (67)
Body mass index kg/m2 (±SD) 25 (±4)
Smoking status at transplantation (%)
Active 38 (15)
Past smoker 98 (38)
Never smoked 120 (47)
Diabetes (%) 37 (14)
Mean pretransplant blood pressure mm Hg (±SD) 147/83 (16/9)
Median pretransplant total cholesterol mmol/L (IQR) 5.12 (4.4–5.9)
Median pretransplant triglycerides mmol/L (IQR) 2 (1.47–2.8)
Cause of renal failure (%)
Glomerular disease 97 (37)
Diabetes 26 (10)
Hypertension or vascular 28 (11)
Other or unknown 105 (42)
Pretransplantation vascular disease (%) 63 (24)
Median time on dialysis pretransplantation 2 (1.3–3.5)
years (IQR)
High (>20%) level of preformed antibodies (%) 50 (19)
Transplantation period (%)
1985 to 1989 56 (22)
1990 to 1994 67 (26)
1995 to 2000 133 (52)
Median donor age years (IQR) 42 (23–51)
Cold ischemia time hours (±SD) 18 (±7.3)
Median number of mismatches (IQR) 3 (2–4)
Use of monoclonal or polyclonal antibodies (%) 84 (32)
Immunosuppression protocol at baseline (%)
Cyclosporine-azathioprine-prednisone 86 (33)
Cyclosporine-prednisone 89 (34)
Tacrolimus-mycophenolate mofetil-prednisone 37 (14)
Cyclosporine-mycophenolate mofetil-prednisone 39 (15)
Tacrolimus-azathioprine or sirolimus-prednisone 3 (1)
Missing information 2 (1)
IRQ is interquartile range.
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Fig. 2. Patient survival, overall and death-censored graft survival.
of cases. The main causes of graft loss were patient death
(73%) and chronic allograft nephropathy (10%), defined
as graft loss occurring in the absence of other causes (vas-
cular, obstructive, recurrent disease, diabetes, toxicity, or
traumatic).
Factors predicting patient survival
Median patient follow-up was 72 months posttrans-
plant. All patients had a minimal observation period of
42 months posttransplant and maximal follow-up was 222
Table 2. Causes of mortality and graft loss
Mortality (N = 112) Number of events (%)
Cardiovascular 51 (46)
Neoplasia 32 (29)
Infection 25 (22)
Other 4 (3)
Graft loss (N = 124) (%) Number of events (%)
Patient death 90 (73)
Chronic allograft nephropathy 12 (10)
Acute rejection 6 (5)
Technical failure/thrombosis 6 (5)
Other 10 (8)
Table 3. Factors predicting patient survival
Predictive variable HR 95% CI
Active smoking at transplantation (reference
nonsmokers)
2.09 (1.22–3.60)
Past smoking at transplantation (reference
nonsmokers)
1.47 (0.89–2.43)
Time on dialysis before transplantation (for
each additional year)
1.10 (1.02–1.18)
Body mass index at transplantation (for a
5-point increase)
1.34 (1.05–1.67)
Transplant period ≥1995 (reference <1995)
for the first 48 months posttransplant
0.44 (0.24–0.80)
Transplant period ≥1995 (reference <1995)
for those surviving past 48 months
posttransplantation
1.18 (0.61–2.31)
Mismatches (per additional mismatch) 1.10 (0.93–1.30)
Diabetes 1.06 (0.61–1.80)
Vascular disease 0.85 (0.53–1.35)
months. A total of 112 patients died during follow-up.
In a multivariate model, active smoking at transplanta-
tion [hazard ratio (HR) 2.09, 95% confidence interval
(CI) 1.22-3.60], BMI at transplantation (HR 1.34 for a
5-point increase, 95% CI 1.05-1.67), and time on dialysis
before transplantation (HR 1.1 for a 1-year increase, 95%
CI 1.02-1.18) were associated with lower patient survival
(Table 3). The effect of the transplantation period was
nonproportional. Hazard plots showed that survival may
have been better for the first 48 months posttransplan-
tation in those transplanted since 1995. However, after
48 months, the hazard function curves overlapped. An
interaction term between the transplantation period and
time (survival for more than 48 months) was created and
added in the multivariate model. The model, including
the interaction term, showed that the recent transplan-
tation period was protective for patient survival in the
first 48 months posttransplant (HR 0.44, 95% CI 0.24-
0.80). Survival of patients beyond 48 months was similar
in those transplanted since 1995 compared with before
1995 (HR 1.18, 95% CI 0.61-2.31). The model also ad-
justed for diabetes and vascular disease. There was no
violation of the proportionality assumption for smoking
status, time on dialysis, and BMI.
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Table 4. Factors predicting overall graft survival
Predictive variable HR 95% CI
Active smoking at transplantation (reference
nonsmokers)
2.04 (1.24–3.30)
Past smoking at transplantation (reference
nonsmokers)
1.23 (0.76–1.97)
Body mass index at transplantation (for a
5-point increase)
1.24 (0.99–1.60)
Transplant period ≥1995 (reference <1995)
after 48 months posttransplant
1.20 (0.61–2.33)
Maximal peak panel reactive antibodies
≥20% (reference <20%)
1.52 (0.94–2.46)
Mismatches (per additional mismatch) 1.13 (0.96–1.32)
Diabetes 0.96 (0.56–1.60)
Donor age ≥50 years (reference <50 years) 1.35 (0.8–2.30)
Factors predicting overall graft survival
During follow-up, there were 124 graft losses in the
cohort. Seventy-three percent of graft losses were due
to patient death. In a multivariate model in which graft
loss was not censored for patient death, active smoking at
transplantation (HR 2.04, 95% CI 1.24-3.30) was the only
risk factor for graft loss (Table 4). Transplantation since
1995 (HR 0.40, 95% CI 0.23-0.70) was a protective factor
for graft loss in the first 48 months posttransplant. After-
wards, this protective effect could not be demonstrated
(HR 1.20, 95% CI 0.61-2.33). There was a trend for an
association between increased BMI and shorter graft sur-
vival (HR 1.24 per 5-point increase, 95% CI 0.99-1.60),
but this was not statistically significant. Donor age older
than 50 years was not significantly associated with overall
graft survival.
Factors predicting treatment failure
Treatment failure, defined as patient death or graft
loss within the first year posttransplantation, occurred
in 31 (12%) patients. Although the initial multivariate
model included the use of MMF versus other, the use
of tacrolimus versus cyclosporine, and the use of poly-
clonal or monoclonal antibodies, these variables were
removed from the final model because they were not as-
sociated with the outcome on multivariate analysis and
to avoid overfit, given the small number of events. The
final multivariate model included four variables. Time on
dialysis before transplantation and recipient age were di-
chotomized because the relationship of these variables
with the logit of the outcome was not linear. Transplanta-
tion since 1995 [odds ratio (OR) 0.28, 95% CI 0.11-0.72]
and recipient age older than 65 years (OR 0.28, 95% CI
0.07-0.97) had a protective effect on treatment failure.
Time on dialysis for 2 years or more before transplan-
tation (OR 3.28, 95% CI 1.34-7.90) was associated with
an increased risk for treatment failure (Table 5). Due to
the small number of events at 1 year, sensitivity analysis
defining treatment failure as patient death or graft loss
Table 5. Predictive model for treatment failure (patient death or
graft loss within the first posttransplant year)
Predictive variable OR 95% CI
Transplant period ≥1995 (reference <1995) 0.28 (0.11-0.72)
Recipient age ≥65 years (reference 60 to 64
years)
0.28 (0.07-0.97)
Time on dialysis before transplantation ≥2
years (reference <2 years)
3.28 (1.34-7.90)
Maximal peak panel reactive antibodies
≥20% (reference <20%)
1.91 (0.77-4.85)
within the first 2 years posttransplantation was performed
to check the robustness of the results. The sensitivity anal-
ysis data were similar to those of the main analysis. The
same predictive factors were identified, except for recipi-
ent age older than 65 years, which did not reach statistical
significance but still seemed to be protective (OR 0.58)
(P = 0.25). In addition, BMI was associated with treat-
ment failure (OR 1.47 for a 5- point increase in BMI)
(P = 0.07), although this was not significant.
DISCUSSION
Elderly recipients are at increased risk of death and
graft loss when compared to their younger counterparts
[6, 13]. Identifying the modifiable predictors of survival
in elderly recipients is crucial to improve their outcome.
We found that the risk of death was higher in active
smokers at the time of transplantation when compared to
patients who had never smoked. Ex-smokers had a ten-
dency toward increased posttransplant mortality when
compared to never smokers. This finding illustrates a dose
response effect in the relationship between smoking and
mortality. It also suggests that smoking cessation while
on the waiting list could put elderly patients in a lower
risk category for posttransplant death. However, there is
no certainty that this will reduce their risk for adverse
outcomes after transplantation, given the damage done
over many years to multiple organ systems. Whether in
a context of organ shortage, elderly smokers should be
excluded from the waiting list because of their reduced
survival is debatable. On the one hand, there is no proof
that elderly smokers do not benefit from transplantation,
and their risk of death is twice that observed in never
smokers, which can not be considered an absolute con-
traindication to transplantation. On the other hand, in
elderly recipients who were active smokers at the time
of transplantation in our cohort, 5-year patient and graft
survival dropped to 64% and 55%, respectively. Whether
these figures are acceptable in terms of fair allocation is
to be judged by individual transplant centers.
Our finding of an adverse impact of longer time on
dialysis before transplantation has clinical implications.
Referral of elderly patients for a transplant evaluation,
for instance, should not be delayed because of their age.
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Furthermore, since the incidence of vascular or infectious
complications in elderly wait-listed patients on dialysis is
high [14], increased time on dialysis might be more detri-
mental to older patients by preventing them from getting
a transplant altogether. Recent data show that recipients
aged 60 years or older who receive a graft from a donor
accepted on the basis of extended criteria (older than 55
years, with more than a 10-year history of hypertension
or diabetes) have better survival than age-matched sub-
jects who remain dialyzed on the waiting list [15]. Thus,
strategies aimed at increasing the donor pool for elderly
recipients, such as living donors or preferential allocation
of older kidney grafts, are worth considering to shorten
waiting time in these patients.
In our study, a higher BMI was associated with an in-
creased risk of death, a result which has never been re-
ported in elderly recipients. This concurs with some [10,
16], but not all [17], studies in general cohorts of trans-
plant recipients. Increasing age and BMI may act syn-
ergistically to decrease survival in transplant recipients,
which could explain the discrepancy between our findings
and those of others [17]. Although our results support
counseling elderly patients on the importance of weight
control before transplantation, they do not suggest a pol-
icy of exclusion of older patients from the waiting list
because of obesity per se.
The effect of receiving a transplant since 1995 was pro-
tective for patient survival in the first 4 years of follow-
up. This protective impact of a recent transplant period
occurred in spite of increased recipient age at transplan-
tation, increased prevalence of diabetes, and older donor
age in patients transplanted since 1995, which may reflect
progress in general medical and posttransplant care. Im-
provement of outcome in the most recent era has been
reported by others [6, 18].
In contrast with the relationship found in the general
kidney transplant population [19], we did not find an as-
sociation between diabetes and patient survival. The ab-
sence of a relationship between diabetes and survival in
elderly recipients has been reported by others [4, 9, 20].
The most likely explanation for this result is a selection
bias, as transplant physicians are likely to accept only the
fittest elderly diabetics on the transplant waiting-list. Our
cohort had few diabetics (14%), and a lack of power may
also limit our findings.
We did not observe an association between pretrans-
plant cardiovascular disease and survival. We think a se-
lection bias is, again, a likely explanation for this finding.
However, two single-center studies have previously re-
ported an association between these variables in elderly
transplant recipients [9, 20]. Different definitions of vas-
cular disease and the intensity of pretransplant screening
procedures may explain these discrepancies. In one of
these studies, pretransplant coronography was routinely
performed [20]. Our study included five transplant cen-
ters. There was no uniform pretransplant vascular screen-
ing protocol among the centers or during the study period.
Hence, cardiovascular disease may have been misclassi-
fied nondifferentially in our cohort, causing a bias toward
the null.
We found treatment failure, defined as patient death or
graft loss in the first posttransplant year, to be relatively
rare (12%). The issue of allocation of a rare resource to
a group of patients who are at greater risk of death and
graft loss is quite important. In our separate analysis for
treatment failure, we did not identify patient character-
istics that could be considered as absolute contraindica-
tions to transplantation in this selected cohort. Our study
was not powered to assess the effect of interactions be-
tween risk factors on survival. However, in patients who
never smoked, had a normal BMI and no history of vas-
cular disease or diabetes, 5-year patient and graft survival
were 81% and 72%, respectively. We believe that these
results show that age per se should not contraindicate
kidney transplantation. Although none of our patients
presented the association of all these risk factors, the lat-
ter excellent survival figures are in contrast to those that
were discussed previously for active smokers.
This study has the following strengths and limitations.
In contrast to large registry-based investigations, we ad-
justed for multiple confounders. Losses to follow-up (2%
of the cohort) were minimal. The multiple imputation
strategy we employed is based on a reasonable assump-
tion of missingness at random, and percent missing data
was low. Our cohort was composed, but for a few excep-
tions, of Caucasians. Hence, our conclusions can only be
generalized to elderly Caucasian recipients of a first kid-
ney graft. Finally, the sample size might not have provided
sufficient power to detect the effect of variables that have
a smaller impact on survival.
CONCLUSION
Our study shows that elderly recipients should be
strongly advised to stop smoking and maintain adequate
body weight before transplantation, and their pretrans-
plant evaluation should not be deferred after the initia-
tion of dialysis. The better survival we observed in elderly
recipients transplanted since 1995 is an encouraging re-
sult, since the proportion of elderly patients on the wait-
ing list is expected to grow in the years to come, given the
sustained increase in the proportion of elderly subjects
initiating renal replacement therapy [4].
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